Empower
Life Science Innovation
Committed to driving the transformation of biotechnology
and empowering the development of innovative enterprises

Learn more

Investment in Life Science

With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.

Learn More

One Team, Global Reach

Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden,  and extensive networks and footprint in Greater China, Asia, USA and Europe.

Learn More

ESG Empowerment

A signatory to the UN PRI and committed to promoting sustainable development and impact investment.

Learn More

Latest News

BOCG·Family | Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
Aug 13, 2025

Recently, Boan Biotech, a portfolio company of Blue Ocean Capital, announced that its independently developed Boyouping® (Dulaglutide Injection) has been granted marketing approval by the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping is the world’s first approved dulaglutide biosimilar, showcasing Boan Biotech’s strong R&D capabilities. Congratulations to Boan Biotech!

BOCG·Family | HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus
Apr 16, 2025

BOCG's portfolio company, HighTide Therapeutics, today announced that two Phase 3 trials of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. HighTide plans to submit a new drug application for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) later this year.Congratulations toHighTide Therapeutics on achieving another important milestone in the clinical development of HTD1801. Looking forward to HighTide Therapeutics bringing safer and more effective treatment options to the large population of type 2 diabetes patients!

BOCG·Family | 1st Milestone Achieved in Ribo’s Collab. With BI
Jan 27, 2025

On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.